Canine Arthritis Treatment Market Report 2025

This Canine Arthritis Treatment market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The canine arthritis treatment market size has grown strongly in recent years. It will grow from $2.35 billion in 2024 to $2.48 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to the aging pet population, growing awareness among pet owners, focus on preventive care, increasing disposable income, and increasing veterinary care expenditure.

The canine arthritis treatment market size is expected to see strong growth in the next few years. It will grow to $3.06 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to a rise in pet insurance coverage, growing cases of arthritis, rising pet ownership rates, growing demand for minimally invasive surgical procedures, and increasing prevalence of arthritis in dogs. Major trends in the forecast period include innovative treatments, advancements in veterinary medicine, demand for advanced therapies, integration of technology, and innovative technologies.

The canine arthritis treatment market is set to grow, driven by the increasing rate of pet ownership. Pet ownership involves caring for domesticated animals for companionship and enjoyment, with factors such as lifestyle changes, pet humanization, and higher disposable incomes contributing to the rising trend. Pet owners utilize treatments for canine arthritis to manage symptoms and improve their dogs' quality of life and mobility. For example, in October 2023, the American Pet Products Association reported that 66% of US households, totaling 86.9 million, owned a pet, indicating the growth in pet ownership driving the canine arthritis treatment market.

Leading companies in this market are innovating treatments such as bedinvetmab injections to address canine joint health and mobility. Bedinvetmab, a monoclonal antibody injection targeting nerve growth factor (NGF) involved in pain, has gained FDA approval. For instance, in May 2023, Zoetis Inc. received FDA approval for Librela, the first monoclonal antibody for dogs, which inhibits canine NGF's biological activity related to pain regulation in osteoarthritis. Administered monthly via subcutaneous injection, Librela offers a convenient, long-term solution for managing canine osteoarthritis pain.

In September 2024, Zoetis, a US-based animal health company specializing in veterinary pain management solutions, partnered with the Arthritis Foundation to raise awareness about osteoarthritis (OA) in pets. This collaboration aims to support educational initiatives that help pet owners identify OA symptoms in dogs and cats, providing tools to improve early detection and manage OA-related pain effectively. The Arthritis Foundation is a US-based nonprofit organization dedicated to the prevention, control, and cure of America’s leading cause of disability.

Major companies operating in the canine arthritis treatment market are Merck & Co. Inc., Bayer AG, Eli Lilly and Company, Zoetis Inc., Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, Royal Canin SAS, Virbac Group, Ceva Sante Animale S.A., Hill's Pet Nutrition Inc., Vetoquinol SA, Norbrook Laboratories Limited, American Regent Inc., Thorne Healthtech Inc., VetStem Inc., Eltech K-Laser s.r.l., Liquid Health Inc, Nutri-Vet LLC, OrthoPets LLC, Rejuvenate Bio Inc.

North America was the largest region in the canine arthritis treatment market in 2024. Asia-Pacifica is expected to be the fastest-growing region in the forecast period. The regions covered in the canine arthritis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the canine arthritis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Canine arthritis treatment involves various medical and therapeutic approaches aimed at addressing the chronic condition characterized by inflammation and progressive cartilage deterioration in a dog's joints. The goal is to reduce pain and inflammation, preserve joint function, and slow down disease progression.

The primary treatments for canine arthritis include drugs, supplements, surgical procedures, and other interventions. Canine arthritis drugs are medications specifically formulated to alleviate symptoms and manage arthritis in dogs. These drugs can be administered orally, parenterally (such as injections), or through other routes, targeting conditions such as osteoarthritis, rheumatoid arthritis, osteochondrosis, and traumatic arthritis. They are distributed through veterinary clinics, hospitals, retail pharmacies, and online platforms, catering to various end-users such as veterinary hospitals, drug stores, and e-commerce platforms.

The canine arthritis treatment research report is one of a series of new reports that provides canine arthritis treatment market statistics, including the canine arthritis treatment industry's global market size, regional shares, competitors with a canine arthritis treatment market share, detailed canine arthritis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the canine arthritis treatment industry. This canine arthritis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The canine arthritis treatment market includes revenues earned by entities by providing services such as extracorporeal shockwave therapy (ESWT), acupuncture, and hyaluronic acid supplements. The market value includes the value of related goods sold by the service provider or included within the service offering. The canine arthritis treatment market also includes sales of gabapentin, adequan canine, and metacam. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.